PRESTIGE CONSUMER HEALTHCARE (PBH) Stock Fundamental Analysis
NYSE:PBH - New York Stock Exchange, Inc. - US74112D1019 - Common Stock - Currency: USD
PBH gets a fundamental rating of 5 out of 10. The analysis compared the fundamentals against 193 industry peers in the Pharmaceuticals industry. PBH scores excellent on profitability, but there are some minor concerns on its financial health. PBH is not valued too expensively and it also shows a decent growth rate.
1. Profitability
1.1 Basic Checks
PBH had positive earnings in the past year.
In the past year PBH had a positive cash flow from operations.
Of the past 5 years PBH 4 years were profitable.
Each year in the past 5 years PBH had a positive operating cash flow.
1.2 Ratios
Looking at the Return On Assets, with a value of 6.43%, PBH belongs to the top of the industry, outperforming 90.81% of the companies in the same industry.
With an excellent Return On Equity value of 11.96%, PBH belongs to the best of the industry, outperforming 89.73% of the companies in the same industry.
Looking at the Return On Invested Capital, with a value of 7.77%, PBH belongs to the top of the industry, outperforming 87.03% of the companies in the same industry.
PBH had an Average Return On Invested Capital over the past 3 years of 7.86%. This is significantly below the industry average of 44.06%.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 6.43% | ||
| ROE | 11.96% | ||
| ROIC | 7.77% |
ROA(3y)3.15%
ROA(5y)3.66%
ROE(3y)6.66%
ROE(5y)8.85%
ROIC(3y)7.86%
ROIC(5y)7.44%
1.3 Margins
Looking at the Profit Margin, with a value of 19.13%, PBH belongs to the top of the industry, outperforming 91.89% of the companies in the same industry.
In the last couple of years the Profit Margin of PBH has grown nicely.
PBH's Operating Margin of 29.56% is amongst the best of the industry. PBH outperforms 92.97% of its industry peers.
PBH's Operating Margin has been stable in the last couple of years.
With a decent Gross Margin value of 55.11%, PBH is doing good in the industry, outperforming 64.32% of the companies in the same industry.
In the last couple of years the Gross Margin of PBH has remained more or less at the same level.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 29.56% | ||
| PM (TTM) | 19.13% | ||
| GM | 55.11% |
OM growth 3Y-1.17%
OM growth 5Y-0.27%
PM growth 3Y2.14%
PM growth 5YN/A
GM growth 3Y-1.48%
GM growth 5Y-0.52%
2. Health
2.1 Basic Checks
PBH has a Return on Invested Capital (ROIC), which is below the Cost of Capital (WACC), which means it is destroying value.
Compared to 1 year ago, PBH has more shares outstanding
PBH has less shares outstanding than it did 5 years ago.
PBH has a better debt/assets ratio than last year.
2.2 Solvency
PBH has an Altman-Z score of 3.03. This indicates that PBH is financially healthy and has little risk of bankruptcy at the moment.
With a decent Altman-Z score value of 3.03, PBH is doing good in the industry, outperforming 73.51% of the companies in the same industry.
The Debt to FCF ratio of PBH is 4.01, which is a neutral value as it means it would take PBH, 4.01 years of fcf income to pay off all of its debts.
PBH's Debt to FCF ratio of 4.01 is amongst the best of the industry. PBH outperforms 88.11% of its industry peers.
PBH has a Debt/Equity ratio of 0.56. This is a neutral value indicating PBH is somewhat dependend on debt financing.
PBH has a Debt to Equity ratio of 0.56. This is in the lower half of the industry: PBH underperforms 65.41% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.56 | ||
| Debt/FCF | 4.01 | ||
| Altman-Z | 3.03 |
ROIC/WACC0.83
WACC9.38%
2.3 Liquidity
A Current Ratio of 3.68 indicates that PBH has no problem at all paying its short term obligations.
PBH has a Current ratio of 3.68. This is comparable to the rest of the industry: PBH outperforms 56.22% of its industry peers.
PBH has a Quick Ratio of 2.20. This indicates that PBH is financially healthy and has no problem in meeting its short term obligations.
Looking at the Quick ratio, with a value of 2.20, PBH is in line with its industry, outperforming 47.03% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 3.68 | ||
| Quick Ratio | 2.2 |
3. Growth
3.1 Past
PBH shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 355.49%, which is quite impressive.
The Earnings Per Share has been growing by 8.45% on average over the past years. This is quite good.
PBH shows a decrease in Revenue. In the last year, the revenue decreased by -1.41%.
Measured over the past years, PBH shows a small growth in Revenue. The Revenue has been growing by 2.89% on average per year.
EPS 1Y (TTM)355.49%
EPS 3Y8.78%
EPS 5Y8.45%
EPS Q2Q%15.09%
Revenue 1Y (TTM)-1.41%
Revenue growth 3Y6.06%
Revenue growth 5Y2.89%
Sales Q2Q%2.68%
3.2 Future
PBH is expected to show a small growth in Earnings Per Share. In the coming years, the EPS will grow by 5.98% yearly.
The Revenue is expected to grow by 1.77% on average over the next years.
EPS Next Y9.07%
EPS Next 2Y7.56%
EPS Next 3Y6.82%
EPS Next 5Y5.98%
Revenue Next Year-0.26%
Revenue Next 2Y0.95%
Revenue Next 3Y1.4%
Revenue Next 5Y1.77%
3.3 Evolution
The EPS growth rate is decreasing: in the next years the growth will be less than in the last years.
When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is decreasing.
4. Valuation
4.1 Price/Earnings Ratio
PBH is valuated rather expensively with a Price/Earnings ratio of 20.20.
Based on the Price/Earnings ratio, PBH is valued cheaply inside the industry as 84.32% of the companies are valued more expensively.
PBH's Price/Earnings ratio indicates a valuation a bit cheaper than the S&P500 average which is at 29.62.
PBH is valuated rather expensively with a Price/Forward Earnings ratio of 17.54.
PBH's Price/Forward Earnings ratio is rather cheap when compared to the industry. PBH is cheaper than 81.08% of the companies in the same industry.
PBH is valuated rather cheaply when we compare the Price/Forward Earnings ratio to 22.70, which is the current average of the S&P500 Index.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 20.2 | ||
| Fwd PE | 17.54 |
4.2 Price Multiples
PBH's Enterprise Value to EBITDA ratio is rather cheap when compared to the industry. PBH is cheaper than 81.08% of the companies in the same industry.
PBH's Price/Free Cash Flow ratio is rather cheap when compared to the industry. PBH is cheaper than 86.49% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 16.86 | ||
| EV/EBITDA | 14.22 |
4.3 Compensation for Growth
The high PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates PBH does not grow enough to justify the current Price/Earnings ratio.
The decent profitability rating of PBH may justify a higher PE ratio.
PEG (NY)2.23
PEG (5Y)2.39
EPS Next 2Y7.56%
EPS Next 3Y6.82%
5. Dividend
5.1 Amount
No dividends for PBH!.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
84.63
-0.16 (-0.19%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)
Earnings (Next)
Inst Owners107.91%
Inst Owner Change-90.41%
Ins Owners1.33%
Ins Owner Change0.86%
Market Cap4.19B
Analysts78.18
Price Target93.33 (10.28%)
Short Float %4.24%
Short Ratio7.05
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)1.91%
Min EPS beat(2)-0.47%
Max EPS beat(2)4.3%
EPS beat(4)2
Avg EPS beat(4)-1.89%
Min EPS beat(4)-14.94%
Max EPS beat(4)4.3%
EPS beat(8)4
Avg EPS beat(8)-70.41%
EPS beat(12)8
Avg EPS beat(12)-46.27%
EPS beat(16)12
Avg EPS beat(16)-31.97%
Revenue beat(2)1
Avg Revenue beat(2)-0.03%
Min Revenue beat(2)-0.39%
Max Revenue beat(2)0.33%
Revenue beat(4)2
Avg Revenue beat(4)-0.77%
Min Revenue beat(4)-4.6%
Max Revenue beat(4)1.57%
Revenue beat(8)3
Avg Revenue beat(8)-0.4%
Revenue beat(12)6
Avg Revenue beat(12)0.17%
Revenue beat(16)10
Avg Revenue beat(16)1.75%
PT rev (1m)4.17%
PT rev (3m)4.17%
EPS NQ rev (1m)0.41%
EPS NQ rev (3m)5.64%
EPS NY rev (1m)1.45%
EPS NY rev (3m)1.7%
Revenue NQ rev (1m)-1.4%
Revenue NQ rev (3m)-0.59%
Revenue NY rev (1m)0%
Revenue NY rev (3m)0.09%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 20.2 | ||
| Fwd PE | 17.54 | ||
| P/S | 3.75 | ||
| P/FCF | 16.86 | ||
| P/OCF | 16.34 | ||
| P/B | 2.34 | ||
| P/tB | N/A | ||
| EV/EBITDA | 14.22 |
EPS(TTM)4.19
EY4.95%
EPS(NY)4.82
Fwd EY5.7%
FCF(TTM)5.02
FCFY5.93%
OCF(TTM)5.18
OCFY6.12%
SpS22.57
BVpS36.1
TBVpS-21.18
PEG (NY)2.23
PEG (5Y)2.39
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 6.43% | ||
| ROE | 11.96% | ||
| ROCE | 10.24% | ||
| ROIC | 7.77% | ||
| ROICexc | 7.89% | ||
| ROICexgc | 74.11% | ||
| OM | 29.56% | ||
| PM (TTM) | 19.13% | ||
| GM | 55.11% | ||
| FCFM | 22.24% |
ROA(3y)3.15%
ROA(5y)3.66%
ROE(3y)6.66%
ROE(5y)8.85%
ROIC(3y)7.86%
ROIC(5y)7.44%
ROICexc(3y)7.97%
ROICexc(5y)7.56%
ROICexgc(3y)99.05%
ROICexgc(5y)101.06%
ROCE(3y)10.37%
ROCE(5y)9.8%
ROICexcg growth 3Y-6.01%
ROICexcg growth 5Y-5.72%
ROICexc growth 3Y6.12%
ROICexc growth 5Y3.46%
OM growth 3Y-1.17%
OM growth 5Y-0.27%
PM growth 3Y2.14%
PM growth 5YN/A
GM growth 3Y-1.48%
GM growth 5Y-0.52%
F-Score7
Asset Turnover0.34
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.56 | ||
| Debt/FCF | 4.01 | ||
| Debt/EBITDA | 2.76 | ||
| Cap/Depr | 25.64% | ||
| Cap/Sales | 0.71% | ||
| Interest Coverage | 6.48 | ||
| Cash Conversion | 71.02% | ||
| Profit Quality | 116.24% | ||
| Current Ratio | 3.68 | ||
| Quick Ratio | 2.2 | ||
| Altman-Z | 3.03 |
F-Score7
WACC9.38%
ROIC/WACC0.83
Cap/Depr(3y)28.35%
Cap/Depr(5y)43.64%
Cap/Sales(3y)0.81%
Cap/Sales(5y)1.32%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)355.49%
EPS 3Y8.78%
EPS 5Y8.45%
EPS Q2Q%15.09%
EPS Next Y9.07%
EPS Next 2Y7.56%
EPS Next 3Y6.82%
EPS Next 5Y5.98%
Revenue 1Y (TTM)-1.41%
Revenue growth 3Y6.06%
Revenue growth 5Y2.89%
Sales Q2Q%2.68%
Revenue Next Year-0.26%
Revenue Next 2Y0.95%
Revenue Next 3Y1.4%
Revenue Next 5Y1.77%
EBIT growth 1Y-5.44%
EBIT growth 3Y4.81%
EBIT growth 5Y2.62%
EBIT Next Year6.42%
EBIT Next 3Y4.36%
EBIT Next 5Y3.4%
FCF growth 1Y10.3%
FCF growth 3Y3.9%
FCF growth 5Y6.01%
OCF growth 1Y9.71%
OCF growth 3Y1.85%
OCF growth 5Y5.63%